Ide, Tatsuya
Koga, Hironori http://orcid.org/0000-0001-5814-9543
Nakano, Masahito
Hashimoto, Satoru
Yatsuhashi, Hiroshi
Higuchi, Nobito
Nakamuta, Makoto
Oeda, Satoshi
Eguchi, Yuichiro
Shakado, Satoshi
Sakisaka, Shotaro
Yoshimaru, Yoko
Sasaki, Yutaka
Honma, Yuichi
Harada, Masaru
Seike, Masataka
Maeshiro, Tatsuji
Miuma, Satoshi
Nakao, Kazuhiko
Mawatari, Seiichi
Ido, Akio
Nagata, Kenji
Matsumoto, Shuichi
Takami, Yuko
Sohda, Tetsuo
Kakuma, Tatsuyuki
Torimura, Takuji
Article History
Received: 26 October 2018
Accepted: 12 February 2019
First Online: 28 February 2019
Compliance with ethical standards
:
: Akio Ido has COI as follows: (1) Speaking fees or honoraria; AbbVie GK, Bristol Myers Squibb Co. Ltd., Gilead Sciences Inc., and Eisai Co. Ltd. (2) Research grants; AbbVie GK, Otsuka Pharmaceutical Co. Ltd., MSD K.K., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Astellas Pharmaceutical Inc., and Takeda Pharmaceutical Co. Ltd. The other authors disclose no conflicts.
: The protocol was approved by all hospital institutional review boards and carried out in compliance with the Declaration of Helsinki.
: Written informed consent was obtained from all participating patients.